Targeting the HIF2–VEGF axis in renal cell carcinoma

TK Choueiri, WG Kaelin Jr - Nature medicine, 2020 - nature.com
Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the testing
of drugs that target the transcription factor HIF or HIF-responsive growth factors, such as …

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

PJ Roberts, CJ Der - Oncogene, 2007 - nature.com
Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in
the regulation of normal cell proliferation, survival and differentiation. Aberrant regulation of …

Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology

RJ Motzer, E Jonasch, N Agarwal, A Alva… - Journal of the National …, 2022 - jnccn.org
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging,
treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage …

Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology

RJ Motzer, E Jonasch, N Agarwal, S Bhayani… - Journal of the National …, 2017 - jnccn.org
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the
clinical management of patients with clear cell and non–clear cell renal carcinoma. These …

Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis

SJ Dixon, DN Patel, M Welsch, R Skouta, ED Lee… - elife, 2014 - elifesciences.org
Exchange of extracellular cystine for intracellular glutamate by the antiporter system xc− is
implicated in numerous pathologies. Pharmacological agents that inhibit system xc− activity …

3D microtumors in vitro supported by perfused vascular networks

A Sobrino, DTT Phan, R Datta, X Wang, SJ Hachey… - Scientific reports, 2016 - nature.com
There is a growing interest in developing microphysiological systems that can be used to
model both normal and pathological human organs in vitro. This “organs-on-chips” …

[HTML][HTML] Sorafenib in advanced clear-cell renal-cell carcinoma

B Escudier, T Eisen, WM Stadler… - … England Journal of …, 2007 - Mass Medical Soc
Background We conducted a phase 3, randomized, double-blind, placebo-controlled trial of
sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients …

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

S Wilhelm, C Carter, M Lynch, T Lowinger… - Nature reviews Drug …, 2006 - nature.com
Since the molecular revolution of the 1980s, knowledge of the aetiology of cancer has
increased considerably, which has led to the discovery and development of targeted …

Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial

B Escudier, T Eisen, WM Stadler, C Szczylik… - Journal of clinical …, 2009 - ascopubs.org
Purpose Mature survival data and evaluation of vascular endothelial growth factor (VEGF)
as a prognostic biomarker from the Treatment Approaches in Renal Cancer Global …

Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis

C Jian, J Fu, XU Cheng, LJ Shen, YX Ji, X Wang, S Pan… - Cell metabolism, 2020 - cell.com
Nonalcoholic steatohepatitis (NASH) is becoming one of the leading causes of
hepatocellular carcinoma (HCC). Sorafenib is the only first-line therapy for advanced HCC …